Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial
- prematurely stopped (insufficient recruitment)
- Prematurely stopped because of insufficient recruitment
Authors' conclusion
GM-CSF had no effect on the prevention of ICU-acquired infection in sepsis immunosuppression, but any conclusion is limited by the early termination of the study leading to low number of included patients.
Study context
- Population
- Adult ICU patients with severe sepsis or septic shock and sepsis-induced immunosuppression (mHLA-DR < 8000 ABC at day 3)
- Participants
- 98 patients
- Comparison
- GM-CSF 125 μg/m² vs placebo for 5 days
- GM-CSFn = 54
- Placebon = 44reference
- Primary endpoint
- Patients with ≥1 ICU-acquired infection
- Follow-up
- Day 28 or ICU discharge
Methodological detailsdouble-blind, placebo-controlled, Groups similar except higher BMI and McCabe score in the GM-CSF group
- Double-blind
- Placebo-controlled
- Groups similar except higher BMI and McCabe score in the GM-CSF group
Primary result
As reported in the abstract
ICU-acquired infection
P = 1.000
Further findings
28-day mortality · no significant difference
P = 0.900
Number or localization of ICU infections
- No significant difference between groups
Original publication
Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial. J Crit Care. Published 31 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →